According to Piper Jaffray, Johnson & Johnson JNJ Neutral rating is maintained.
Piper Jaffray said that, after a long wait, the approval of Xarelto for the prevention of DVT following knee and hip replacement comes as a bit of a relief, two years after an FDA panel recommended approval. “We remain Neutral on JNJ primarily due to the company's consent decree with the FDA regarding the OTC business, and the risk that it could potentially widen over the next 12-24 months.”
Johnson & Johnson closed on Friday at $67.30.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in